Ascletis Pharma announces that its wholly owned subsidiary Ascletis Pharmaceuticals has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., a subsidiary of Simcere Pharmaceutical Group Limited.
Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral protease inhibitors. Ascletis currently owns the only authorized ritonavir oral tablet in China, which has passed bioequivalence study.